Neurogene expands Rett syndrome trial, doses third patient By Investing.com
[ad_1] © Reuters. NEW YORK – Neurogene Inc. (NASDAQ: NGNE), a biotechnology firm focused on developing genetic therapies for rare neurological diseases, announced today that...